C07C 63/08
Salts thereof
C07C63/08 (Salts thereof) appears on 64 US grants and 87 published applications in this corpus.
Search patents in C07C- Granted patents
- 64
- Published applications
- 87
- Assignees
- 60
- Inventors
- 229
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 3 |
| 2012 | 0 | 3 |
| 2013 | 2 | 1 |
| 2014 | 2 | 3 |
| 2015 | 2 | 1 |
| 2016 | 2 | 6 |
| 2017 | 3 | 6 |
| 2018 | 3 | 7 |
| 2019 | 6 | 5 |
| 2020 | 4 | 3 |
| 2021 | 4 | 4 |
| 2022 | 2 | 11 |
| 2023 | 5 | 6 |
| 2024 | 3 | 12 |
| 2025 | 7 | 7 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Psilocybin analogs, salts, compositions, and methods of use15 Sep 2026US 12,735,386 B2Cybin IRL Limited
- Salts of nitrogen-containing heterocyclic compound, and solid forms of salts, pharmaceutical composition and use thereof26 May 2026US 12,637,470 B2Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
- Alpha-1062 for treating traumatic brain injury31 Mar 2026US 12,589,099 B2Alpha Cognition Inc.
- Pharmaceutically acceptable salts of psilocin and uses thereof10 Feb 2026US 12,545,642 B2Eleusis Therapeutics US, Inc.
- LSD salt crystal forms27 Jan 2026US 12,534,460 B2Mind Medicine, Inc.
- Psilocybin analogs, salts, compositions, and methods of use27 Aug 2026US 2026/0250246 A1Cybin IRL Limited
- Quaternary ammonium compounds (qacs) and process for preparation thereof30 Jul 2026US 2026/0216116 A1
- Alpha-1062 for treating traumatic brain injury23 Jul 2026US 2026/0207617 A1Alpha Cognition Inc.
- Lsd salt crystal forms23 Jul 2026US 2026/0209229 A1Definium Therapeutics US, Inc.
- Psilocin crystalline forms26 Mar 2026US 2026/0085039 A1TRYP Therapeutics Inc.
Most cited
By later US patents
- Salt forms of a xanthine compound44US 8,865,729 B2Boehringer Ingelheim International GmbH · 2014
- Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine34US 9,212,183 B2Boehringer Ingelheim International GmbH · 2015
- Nicotine salt with meta-salicylic acid22US 9,724,341 B2Alexza Pharmaceuticals, Inc. · 2017
- Cerium (IV) catalyst compounds and promoting combustion of hydrocarbon fuels therewith21US 5,449,387 ARhone-Poulenc Chemicals Limited · 1995
- Pharmaceutically acceptable salts of psilocin and uses thereof18US 11,312,684 B1Eleusis Therapeutics US, Inc. · 2022